The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Open accessAbstract
BACKGROUND: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. We conducted a phase 3 trial to evaluate the safety and efficacy of 52 weeks of treatment with evolocumab. METHODS: We stratified patients with hyperlipidemia according to the risk categories outlined by the Adult Treatment Panel III of the National Cholesterol Education Program. On the basis of this classification, patients were started on background lipid-lowering therapy with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe at a dose of 10 mg daily, for a run-in period of 4 to 12 weeks. Patients with an LDL cholesterol level of 75 mg per deciliter (1.9 mmol per liter) or higher were then randomly assigned in a 2:1 ratio to receive either evolocumab (420 mg) or placebo every 4 weeks. The primary end point was the percent change from baseline in LDL cholesterol, as measured by means of ultracentrifugation, at week 52. RESULTS: Among the 901 patients included in the primary analysis, the overall least-squares mean (±SE) reduction in LDL cholesterol from baseline in the evolocumab group, taking into account the change in the placebo group, was 57.0±2.1% (P<0.001). The mean reduction was 55.7±4.2% among patients who underwent background therapy with diet alone, 61.6±2.6% among those who received 10 mg of atorvastatin, 56.8±5.3% among those who received 80 mg of atorvastatin, and 48.5±5.2% among those who received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for all comparisons). Evolocumab treatment also significantly reduced levels of apolipoprotein B, non-high-density lipoprotein cholesterol, lipoprotein(a), and triglycerides. The most common adverse events were nasopharyngitis, upper respiratory tract infection, influenza, and back pain. CONCLUSIONS: At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks. (Funded by Amgen; DESCARTES ClinicalTrials.gov number, NCT01516879.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment of hyperlipidemic patients with monoclonal antibodies that target and inactivate PCSK9 results in increased hepatic LDLR expression and significantly reduced plasma LDL-C40,41.”
From RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels (2023) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with PCSK9 inhibitors reduces LDL-C by approximately − 60% [75–79].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [79]
The cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“ASO silencing of Rnf130 resulted in a 50% decrease in LDL-C, a change comparable to inhibiting PCSK940,41, further supporting that RNF130 is a significant regulator of LDLR and LDL-C levels.”
From RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels (2023) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 579
Self-citationMcKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 514
Self-citationRaal, F. J., Scott, R. C., Somaratne, R. M., Bridges, I. M., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 506
Self-citationAtorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., & Stein, E. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201832 · Cited by 462
Self-citationLambert (2012) · doi:10.1194/jlr.r026658 · Cited by 448
Sullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.25790 · Cited by 447
Self-citationGiugliano, R. P., Desai, N. R., Kohli, P., Rogers, W. J., Somaratne, R. M., Huang, F., Liu, T., Mohanavelu, S., Hoffman, E. B., McDonald, S. T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61770-x · Cited by 428
Self-citation
Flagged first, then by citations
1 of the 16 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 722
Oesterle, A., & Liao, J. K. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180817155058 · Cited by 82
Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management
Najam, O., & Ray, K. K. (2015) · Cardiology and Therapy · doi:10.1007/s40119-015-0037-z · Cited by 84
Ason, B. L., van der Hoorn, J. W. A., Chan, J. C. Y., Lee, E. W., Pieterman, E. J., Nguyen, K., Di, M., Shetterly, S., Tang, J. T., Yeh, W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m053207 · Cited by 83
Self-citationTada, H., Kawashiri, M., Yoshida, T., Teramoto, R., Nohara, A., Konno, T., Inazu, A., Mabuchi, H., Yamagishi, M., & Hayashi, K. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0999 · Cited by 79
Li, C., Lin, L., Zhang, W., Zhou, L., Wang, H., Luo, X., Luo, H., Cai, Y., & Zeng, C. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.001937 · Cited by 77
Jackson, N. C., Atar, D., Borentain, M., Breithardt, G., van Eickels, M., Endres, M., Fraass, U., Friede, T., Hannachi, H., Janmohamed, S. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv213 · Cited by 79
PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia
Saavedra, Y. G. L., Dufour, R., Davignon, J., & Baass, A. W. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304406 · Cited by 77
Role of PCSK9 beyond liver involvement
Cariou, B., Si‐Tayeb, K., & May, C. L. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000180 · Cited by 85
Cao, Y., Li, S., Liu, H., & Li, J. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022348 · Cited by 77
Toth, P. P., Descamps, O. S., Genest, J. J., Sattar, N. A., Preiss, D., Dent, R. E., Djedjos, C. S., Wu, Y., Geller, M. L., Uhart, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025233 · Cited by 76
Self-citationRole of PCSK9 in lipid metabolism and atherosclerosis
Lin, X., Xiao, L., Tang, Z., Jiang, Z., & Liu, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.024 · Cited by 78
Khan, A. R., Bavishi, C., Riaz, H., Farid, T., Khan, S., Atlas, M., Hirsch, G. A., Ikram, S., & Bolli, R. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003153 · Cited by 72
Xie, W., Liu, J., Wang, W., Wang, M., Qi, Y., Zhao, F., Sun, J., Liu, J., Li, Y., & Zhao, D. H. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.103 · Cited by 73
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 71
Klose, G., Laufs, U., März, W., & Windler, E. E. T. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0523 · Cited by 73
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
Bardolia, C., Amin, N. S., & Turgeon, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.789931 · Cited by 69
PCSK9 inhibitors and cardiovascular disease
Chapman, M. J., Stock, J. K., & Ginsberg, H. N. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000239 · Cited by 66
Nicholls, S. J., Nissen, S. E., Prati, F., Windecker, S., Kataoka, Y., Puri, R., Hucko, T., Kassahun, H., Liao, J., Somaratne, R. M., et al. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-684 · Cited by 65
Swiger, K. J., & Martin, S. S. (2015) · Drug Safety · doi:10.1007/s40264-015-0296-6 · Cited by 65
Blom, D. J., Koren, M. J., Roth, E. M., Monsalvo, M. L., Djedjos, C. S., Nelson, P., Elliott, M., Wasserman, S. M., Ballantyne, C. M., & Holman, R. R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12788 · Cited by 64
Self-citationFarmakis, I. T., Doundoulakis, I., Pagiantza, A., Zafeiropoulos, S., Antza, C., Karvounis, H. I., & Giannakoulas, G. A. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000963 · Cited by 64
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
“Efficacy appears similar across most patient subgroups, including heterozygous FH patients.(78,79) PCSK9 mAbs allowed a substantial proportion of FH patients to achieve LDL cholesterol <1.”
BackgroundNontraditional Serum Lipid Variables and Recurrent Stroke Risk
Park, J., Lee, J., & Ovbiagele, B. (2014) · Stroke · doi:10.1161/strokeaha.114.006827 · Cited by 62
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61
Cao, Y., Liu, H., Dong, Q., Li, S., & Li, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13235 · Cited by 61
Khan, S. U., Talluri, S., Riaz, H., Rahman, H., Nasir, F., Bin Riaz, I., Sattur, S., Ahmed, H., Kaluski, E., & Krasuski, R. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318766612 · Cited by 61
Grześk, G., Dorota, B., Wołowiec, Ł., Wołowiec, A., Osiak, J., Kozakiewicz, M., & Banach, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113957 · Cited by 64
Using ALoFT to determine the impact of putative loss-of-function variants in protein-coding genes
Balasubramanian, S., Fu, Y., Pawashe, M., McGillivray, P. D., Jin, M., Liu, J., Karczewski, K. J., MacArthur, D. G., & Gerstein, M. (2017) · Nature Communications · doi:10.1038/s41467-017-00443-5 · Cited by 62
Lacy, M., Atzler, D., Liu, R., de Winther, M. P. J., Weber, C., & Lutgens, E. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.012 · Cited by 69
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease
Klug, E. Q., Llerena, S., Burgess, L. J., Fourie, N., Scott, R. S., Vest, J., Caldwell, K., Kallend, D. G., Stein, E. A., & LIBERATE-HR Investigators (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.1659 · Cited by 61
Self-citationEvolocumab (AMG 145) for primary hypercholesterolemia
Langslet, G., Emery, M. G., & Wasserman, S. M. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1030395 · Cited by 62
Self-citationUnderstanding PCSK9 and anti-PCSK9 therapies
McKenney, J. M. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.01.001 · Cited by 62
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Ito, M. K., & Santos, R. D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.766 · Cited by 59
Faludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 61
Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management
Mytilinaiou, M. G., Kyrou, I., Khan, M., Grammatopoulos, D. K., & Randeva, H. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00707 · Cited by 61
Walley, K. R., Francis, G. A., Opal, S. M., Stein, E. A., Russell, J. A., & Boyd, J. H. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0876ci · Cited by 58
Self-citationBertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 59
Wang, X., Chen, X., Zhang, X., Su, C., Yang, M., He, W., Du, Y., Si, S., Wang, L., & Hong, B. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102650 · Cited by 58
Proprotein Convertase Subtilisin/Kexin 9 Inhibitors
Dragan, S. R., Șerban, M.-C., & Banach, M. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414539562 · Cited by 58
Lipids, blood pressure and kidney update 2015
Banach, M., Aronow, W. S., Șerban, M.-C., Rysz, J., Voroneanu, L. E., & Covic, A. C. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 57
Toth, P. P., Bray, S., Villa, G., Palagashvili, T., Sattar, N., Stroes, E. S. G., & Worth, G. M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025551 · Cited by 56
Self-citationJoseph, L., & Robinson, J. G. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.04.004 · Cited by 59
Baruch, A., Mosesova, S., Davis, J. D., Budha, N. R., Vilimovskij, A., Kahn, R., Peng, K., Cowan, K. J., Harris, L. P., Gelzleichter, T. R., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.02.020 · Cited by 56
PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
Nicholls, S. J. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0030 · Cited by 58
Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia
Zhao, Z., Du, S., Shen, S., Luo, P., Ding, S., Wang, G., & Wang, L. (2019) · Medicine · doi:10.1097/md.0000000000014400 · Cited by 55
Grimaudo, S., Bartesaghi, S., Rametta, R., Marra, F., Mancina, R. M., Pihlajamäki, J., Kakol‐Palm, D., Andréasson, A., Dongiovanni, P., Fracanzani, A. L., et al. (2020) · Liver International · doi:10.1111/liv.14711 · Cited by 54
Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk
Saavedra, Y. G. L., Dufour, R., & Baass, A. W. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.08.005 · Cited by 54
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
Kosmas, C. E., Skavdis, A., Sourlas, A., Papakonstantinou, E. J., Genao, E. P., Uceta, R. E., & Guzman, E. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288831 · Cited by 53
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
Safarova, M. S., Bimal, T., Soffer, D. E., Hirsh, B. J., Shapiro, M. D., Mintz, G. L., Cha, A., & Gianos, E. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100701 · Cited by 52
Adipose-Derived Mesenchymal Stem Cells Ameliorate Lipid Metabolic Disturbance in Mice
Liu, G.-Y., Liu, J., Wang, Y., Liu, Y., Shao, Y., Han, Y., Qin, Y.-R., Xiao, F., Li, P., Zhao, L., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0239 · Cited by 52
Crosstalk of Hyperglycemia and Dyslipidemia in Diabetic Kidney Disease
Su, W., Cao, R. Y., He, Y., Guan, Y. F., & Ruan, X. Z. (2017) · Kidney Diseases · doi:10.1159/000479874 · Cited by 55
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 52
Wang, H., Wang, Q., Wang, J., Guo, C., Kleiman, K., Meng, H., Knight, J. S., & Eitzman, D. T. (2017) · Scientific Reports · doi:10.1038/s41598-017-14307-x · Cited by 51
A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels
Cao, Y., Liu, H., Li, S., & Li, J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0303-2 · Cited by 51
Tang, Y., Li, S., Hu, J., Sun, K., Liu, L., & Xu, D. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01009-4 · Cited by 52
Low LDL cholesterol by PCSK9 variation reduces cardiovascular mortality
Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.517 · Cited by 51
The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis
Au, A., Griffiths, L. R., Cheng, K., Kooi, C. W., Looi, I., & Wei, L. K. (2015) · Scientific Reports · doi:10.1038/srep18224 · Cited by 50
Si‐Tayeb, K., Idriss, S., Champon, B., Caillaud, A., Pichelin, M., Arnaud, L., Lemarchand, P., May, C. L., Zibara, K., & Cariou, B. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.022277 · Cited by 54
PCSK9 inhibitors in the prevention of cardiovascular disease
Latimer, J., Batty, J. A., Neely, R. D. G., & Kunadian, V. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1364-1 · Cited by 50
Athyros, V. G., Katsiki, N., Karagiannis, A. I., & Mikhailidis, D. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1053464 · Cited by 48
Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
Strilchuk, L. M., Fogacci, F., & Cicero, A. F. G. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1620730 · Cited by 48
Yadav, K., Sharma, M., & Ferdinand, K. C. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.05.006 · Cited by 48
Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Dijk, W., May, C. L., & Cariou, B. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.03.013 · Cited by 49
Incidence of cardiovascular disease in familial combined hyperlipidemia: A 15-year follow-up study
Luijten, J., van Greevenbroek, M. M. J., Schaper, N. C., Meex, S. J. R., van der Steen, C., Meijer, L. J., de Boer, D., Graaf, J. D., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.013 · Cited by 47
Keep recycling going: new approaches to reduce LDL-C
Klein-Szanto, A. J. P., & Bassi, D. E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.003 · Cited by 46
KEECH, A. C., Oyama, K., Sever, P., Tang, M., Murphy, S. A., Hirayama, A., Lu, C., Tay, L., DEEDWANIA, P. C., Siu, C., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-1051 · Cited by 46
Non-alcoholic fatty liver disease: a narrative review of genetics
Christopher, J., Zemin, Y., & Jiang, Z. G. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.32.20180045 · Cited by 46
Yang, Q., Sun, D., Pei, C., Zeng, Y. H., Wang, Z., Li, Z., Hao, Y., Song, X., Li, Y., Liu, G., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab418 · Cited by 45
Rosei, E. A., & Salvetti, M. (2016) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-016-0155-2 · Cited by 47
Chen, H., Chen, P., Wu, M., Tai, M., & Yen, J.-H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162414 · Cited by 45
Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors
Hines, D. M., Rane, P., Patel, J. G., Harrison, D. J., & Wade, R. L. (2018) · Vascular Health and Risk Management · doi:10.2147/vhrm.s180496 · Cited by 45
PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension
Berger, J.-M., Vaillant, N., May, C. L., Calderon, C., Brégeon, J., Prieur, X., Hadchouel, J., Loirand, G., & Cariou, B. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.012 · Cited by 52
Awan, Z. A., Baass, A. W., & Genest, J. J. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.225946 · Cited by 44
PCSK9 inhibitors and cardiovascular outcomes
Steffens, D., Bramlage, P., Scheeff, C., Kašner, M., Hassanein, A., Friebel, J., & Rauch‐Kröhnert, U. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1677604 · Cited by 46
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Wołowiec, Ł., Osiak, J., Wołowiec, A., Wijata, A., Grześk, E., Kozakiewicz, M., Banach, J., Nowaczyk, A., Nowaczyk, J., & Grześk, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020323 · Cited by 43
PHARMACIST'S LETTER / PRESCRIBER'S LETTER
Symptoms, S. M., & Intolerance, M. S. (2015) · Cited by 43
Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 43
Edmiston, J. B., Brooks, N. A., Tavori, H., Minnier, J., Duell, B., Purnell, J. Q., Kaufman, T. M., Wójcik, C., Vörös, S., Fazio, S., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.03.001 · Cited by 43
Qian, L., Gao, Y., Zhang, Y. M., Chu, M., Yao, J., & Xu, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-00316-3 · Cited by 43
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables
Filippatos, T. D., Kei, A. A., Rizos, C. V., & Elisaf, M. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417724868 · Cited by 46
An update on pharmacotherapies in diabetic dyslipidemia
Gupta, M., Tummala, R., Ghosh, R. K., Blumenthal, C., Philip, K., Bandyopadhyay, D., Ventura, H. O., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.006 · Cited by 43
New Therapies for Reducing Low-Density Lipoprotein Cholesterol
Stein, E. A., & Raal, F. J. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.008 · Cited by 42
Self-citationNissen, S. E., Dent-Acosta, R. E., Rosenson, R. S., Stroes, E. S. G., Sattar, N. A., Preiss, D., Mancini, G. B. J., Ballantyne, C. M., Catapano, A. L., Gouni‐Berthold, I., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22518 · Cited by 42
Self-citationKhoury, P. E., Elbitar, S., Ghaleb, Y., Khalil, Y. A., Varret, M., Boileau, C., & Abifadel, M. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0684-8 · Cited by 46
Casula, M., Olmastroni, E., Boccalari, M. T., Tragni, E., Pirillo, A., & Catapano, A. L. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.021 · Cited by 44
Insight into the Evolving Role of PCSK9
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R. J., & Okopień, B. (2022) · Metabolites · doi:10.3390/metabo12030256 · Cited by 41
Besseling, J., Sjouke, B., & Kastelein, J. J. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.011 · Cited by 41
Gouni‐Berthold, I., Descamps, O. S., Fraass, U., Hartfield, E., Allcott, K., Dent, R. E., & März, W. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13066 · Cited by 41
Lorenzatti, A. J., Eliaschewitz, F. G., Chen, Y., Lu, J., Baass, A. W., Monsalvo, M. L., Wang, N., Hamer, A. W., & Ge, J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13680 · Cited by 41
Self-citationPCSK9 inhibitors: current status and emerging frontiers in lipid control
Agnello, F. G., Mauro, M. S., Rochira, C., Landolina, D., Finocchiaro, S., Greco, A., Ammirabile, N., Raffo, C., Mazzone, P. M., Spagnolo, M., et al. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2288169 · Cited by 43
PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
Norata, G. D., Tibolla, G., & Catapano, A. L. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.05.011 · Cited by 41
Sattar, N. A., Toth, P. P., Blom, D. J., Koren, M. J., Soran, H., Uhart, M., Elliott, M., Cyrille, M., Somaratne, R. M., & Preiss, D. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.07.047 · Cited by 40
Self-citationPCSK9 inhibitors – past, present and future
Reiner, Ž. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1075506 · Cited by 41
McCormack, T., Dent, R., & Blagden, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12881 · Cited by 39
Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data
Cicero, A. F., Tartagni, E., & Ertek, S. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.932348 · Cited by 39
Human knockout research: new horizons and opportunities
Alkuraya, F. S. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.11.003 · Cited by 41
The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies
Lambert, G. C., Thedrez, A., Croyal, M., Ramin‐Mangata, S., Couret, D., Diotel, N., Nobécourt, E., Krempf, M., LeBail, J. C., Poirier, B., et al. (2017) · Clinical Science · doi:10.1042/cs20160403 · Cited by 41
Strategies to Uplift Novel Mendelian Gene Discovery for Improved Clinical Outcomes
Seaby, E. G., Rehm, H. L., & O’Donnell‐Luria, A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.674295 · Cited by 41
Advancements in Serine Protease Inhibitors: From Mechanistic Insights to Clinical Applications
Wei, Y., Huang, M., & Jiang, L. (2024) · Catalysts · doi:10.3390/catal14110787 · Cited by 38
PCSK9 and triglyceride-rich lipoprotein metabolism
Irena, D., Hussein, A., & Ooi, T. C. (2015) · Journal of Biomedical Research · doi:10.7555/jbr.29.20150052 · Cited by 39
Metadata
- Authors
- Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., Monsalvo, M. L., Tsirtsonis, K., Kim, J. B., Scott, R., Wasserman, S. M., & Stein, E. A.
- Affiliations
- University of Cape Town (ZA)
- National Institutes of Health (US)
- Midwest Institute for Clinical Research (US)
- Stellenbosch University (ZA)
- Sterling Research Group (US)
- Jacksonville Center for Clinical Research (US)
- Houston Methodist (US)
- Amgen (United States) (US)
- Amgen (United Kingdom) (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-08
- Volume
- 370
- Issue
- 19
- Pages
- 1809-1819
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2155259933
- Semantic Scholar
- 8d480541d9ba40d0cf45fea465f3b42bfc2b2f19
- Cited by
- 720
- References
- 16
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 44 · 2023: 44 · 2022: 26 · 2021: 33 · 2020: 46 · 2019: 49 · 2018: 62 · 2017: 92 · 2016: 110 · 2015: 103 · 2014: 48
- FWCI
- 116.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Open University of Cape Town (University of Cape Town) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evolocumab, PCSK9 inhibition, hyperlipidemia, LDL cholesterol lowering, monoclonal antibodies, atorvastatin, ezetimibe, apolipoprotein B, lipoprotein(a), triglycerides, non-HDL cholesterol, treatment safety
- MeSH terms
- Atorvastatin, Ezetimibe, Proprotein Convertase 9, Adult, Aged, Antibodies, Monoclonal, Azetidines, Combined Modality Therapy, Double-Blind Method, Female, Heptanoic Acids, Humans, Hyperlipidemias, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Serine Endopeptidases, Least-Squares Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Proprotein Convertases, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
